6ML vs BIOV: Side-by-Side Comparison
Compare MOLECULAR PARTNERS SF 1 (6ML) and Bioversys AG (BIOV) side by side: market cap EUR 126.79M vs CHF 152.05M. Financials, growth and model signals on Bullrun.
| Metric | 6ML | BIOV |
|---|---|---|
| Company | MOLECULAR PARTNERS SF 1 | Bioversys AG |
| Country / Exchange | Switzerland · F | Switzerland · SW |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Market cap | EUR 126.79M | CHF 152.05M |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Valuation model | — | — |
| Revenue (latest FY) | — | CHF 800.00K |
| Revenue growth YoY | — | — |
| Net income | — | CHF -21.83M |
| Gross margin | — | -386.6% |
| Diluted EPS | — | -3.89 |